Octoplus« Terug naar discussie overzicht

1. [verwijderd] 28 september 2011 15:24

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Er is al gesproken over deze presentaie in een ander draadje maar ik vond het wel de moeite waard om hier een apart draadje van te maken.
   
   Want....wat een potentie heeft dit aandeel. Er wordt zo maar gesproken over milestone betalingen van 138 milljoen USD !! Daar kan menigeen pharmaceutisch bedrijf zijn vingers bij aflikken.
   
   Zie voornamelijk de pagina's 5 ; 18 en 30
   
   www.octoplus.nl/index.cfm/octoplus/in...
   
   en klik op "Investors presentation september 2011 "
2. [verwijderd] 28 september 2011 23:11

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   
   Novartis, 1 van de partners van Octoplus, heeft zijn cijfers bekend gemaakt.
   
   Highlights: 14 % meer netto verkopen, blijven investeren
   in onderzoek en ontwikkeling en de ontwikkeling voor Hepatities C ( Locteron ) valt daar onder
   
   The most promising product pipeline belongs to Novartis, which generated a 14% net sales increase and received 13 major regulatory approvals in 2010. The company's principal goal is to discover new medicines for diseases with significant unmet medical needs. The company's core operating income rose 22% to $14 billion and core net income was up 17% to $12 billion. R&D expenses of $9.07 billion accounted for nearly 18% of Novartis' net sales.
   
   Novartis' 13 major regulatory approvals in 2010 included Gilenya for multiple sclerosis in the U.S., and new indications for Lucentis for the treatment of diabetic macular edema in the EU as well as Tasigna for newly diagnosed CML in the U.S., EU, and Japan. Other key approvals included a new vaccine, Menveo, in the U.S. and EU as well as FDA approval for generic Enoxaparin. The Swiss company has at least seven more potential blockbusters in the pipeline.
   
   "Unlike some other leading companies that are cutting R&D expenses, Novartis intends to continue heavily investing in research and development," says Andrew Humphreys, editor in chief of UBM Canon Data Products. "Of the company's 140-plus pipeline projects, more than 60 are new molecular entities including potential first-in-class blockbuster medicines for chronic obstructive pulmonary disease, hepatitis C, rheumatoid arthritis, and psoriasis.”
   More information on the outlook for this market, new technologies, and segment leaders is available in Top 50 Pharmaceutical Companies and Their Pipelines 2011, located at www.pharmalive.com/specialreports.
   
   
3. [verwijderd] 30 september 2011 09:32

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Wat gaat Octoplus doen vandaag ?? Gisteren al 14% erbij en de bied loopt lekker vol. Ontwikkelingen bij Locteron ? Uitbreiding bestaande partners ? Nieuwe milestone betalingen onderweg ??
4. [verwijderd] 30 september 2011 16:26

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Koers blijft goed liggen. Bodem lijkt gevormd en de uitbraak naar boven is dichtbij.
5. [verwijderd] 3 oktober 2011 00:05

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Gezien de presentatie van Octoplus zelf lijkt het er op dat ze extra cash niet nodig hebben (meer niet-Locteron omzet en minder kosten). Als dat zo is, zou een persbericht wel fijn zijn. De koers staat nl. onder druk na de kaspositie in de laatste cijferpresentatie. "Onze kaspositie is toereikend tot ....") zou een welkom bericht zijn. Ze hoeven van mij de markt niet gek te maken met persberichten (zoals voorheen Crucell),maar iets meer info omtrent de kaspositie doet wonderen (de free floot is beperkt en emissies zijn tot op heden onderhands gegaan i.p.v. claimemissies).
   
   Gr.NLLFE
6. [verwijderd] 3 oktober 2011 10:58

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Inderdaad weinig handel. Geen kopers maar misschien nog wel belangrijker ook geen verkopers.
   Dit fonds kan dan ook zo maar gaan knallen bij een bericht / PB.
   
7. [verwijderd] 3 oktober 2011 14:17

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Investors & Media
   
   News Release
   
   << Back
   
   The Medicines Company Settles Angiomax(R) (Bivalirudin) Patent Litigations With Teva
   
   PARSIPPANY, NJ, Oct 03, 2011 (MARKETWIRE via COMTEX) --
   
   The Medicines Company (NASDAQ: MDCO) today announced that it has settled the lawsuits filed by MDCO in the U.S. District Court for the District of Delaware relating to the Abbreviated New Drug Applications (ANDAs) filed by Teva Parenteral Medicines, Inc. and its affiliate, Pliva Hrvatska d.o.o. (collectively "Teva"), for generic versions of Angiomax(R) (bivalirudin for injection). The settlement includes a license by MDCO to Teva Pharmaceuticals USA, Inc. and its affiliates under which Teva may launch a generic bivalirudin product under one of its ANDAs in the U.S. on June 30, 2019. In certain limited circumstances, MDCO's license to Teva would become effective prior to June 30, 2019.
   
   
   As part of the agreement, Teva admits that the two patents asserted in the lawsuits are valid and enforceable against, and would be infringed by, Teva's proposed generic bivalirudin products. The patents at issue in the litigation are listed in the Orange Book and expire on July 27, 2028.
   
   MDCO also entered into an agreement with Teva under which Teva will supply bivalirudin active pharmaceutical ingredient (API) to MDCO. This provides an additional source of API to support planned growth of product use.
   
   "This result reflects our continued confidence in the strength of our patents, and we will continue to vigorously defend our intellectual property," said Dr. Clive Meanwell, Chairman and CEO of The Medicines Company. "We are delighted to partner with Teva who will provide us needed additional manufacturing capacity and a second source of high quality Angiomax(R) active ingredient which we can finish, fill and supply to our hospital customers for millions of patients."
   
   As required by law, MDCO and Teva will submit the agreements to the U.S. Federal Trade Commission and the U.S. Department of Justice.
   
   Background on the litigation now settled.
   
   On September 4, 2009, MDCO announced that it had received a Paragraph IV Certification Notice Letter from Teva notifying MDCO that Teva had submitted ANDAs to the Food and Drug Administration for approval to market generic versions of Angiomax(R). On October 8, 2009 and December 28, 2009, MDCO filed patent infringement lawsuits against the Teva defendants. The complaints, which were filed in the U.S. District Court for the District of Delaware, alleged infringement of U.S. Patent Nos. 7,582, 727 and 7,598,343, which expire on July 27, 2028.
   
   MDCO remains in infringement litigations involving U.S. Patent Nos. 7,582, 727 and 7,598,343 with APP Pharmaceuticals, Hospira, Mylan Pharmaceuticals, and Dr. Reddy's Laboratories.
   
   About The Medicines Company The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients. The Medicines Company's website is www.themedicinescompany.com.
   
   Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions, including the Company's preliminary revenue results, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include the extent of the commercial success of Angiomax, the Company's ability to develop its global operations and penetrate foreign markets, whether the Company's products will advance in the clinical trials process on a timely basis or at all, whether the Company is able to obtain or maintain patent protection for the intellectual property relating to the Company's products, whether the Company will make regulatory submissions for product candidates on a timely basis, whether its regulatory submissions will receive approvals from regulatory agencies on a timely basis or at all, whether physicians, patients and other key decision makers will accept clinical trial results, risks associated with the establishment of international operations, and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on August 2, 2011, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.
   Contact:
   Michael Mitchell
   The Medicines Company
   973-290-6000
   investor.relations@themedco.com
   
   
   SOURCE: The Medicines Company
   
   
8. Mr sponge 5 oktober 2011 15:15

   auteur info

   •    Mr sponge

     Lid sinds: 16 jan 2001

     Laatste bezoek: 13 aug 2024

   •    Aanbevelingen

     Ontvangen: 553

     Gegeven: 178

   •    Aantal posts: 2.447

   Op xea zien ze het wel zitten.
   Daar wordt Octoplus steeds vaker besproken.
   Ok Xea staat vol met taalfouten en hun adviezen zijn niet altijd succesvol. Maar hun kijk op Octoplus komt wel overeen met die van mij.
   Zie: 13.17uur
   www.xea.nl/advies-dag.php?type=toon&a...
   Al geloof ik niet dat de productie van het FaseIII materiaal dit kwartaal al begint.